XPH: Healthcare Dashboard For July

A top-down analysis of the healthcare sector reveals healthcare providers are significantly undervalued with good quality, while pharmaceuticals/biotechnology are near historical valuation baselines and also show good quality. However, the SPDR S&P Pharmaceuticals ETF (XPH), a modified equal-weighted fund, has notably underperformed the broader Health Care Select Sector SPDR ETF (XLV) by 3.7 percentage points annualized since 2006, having traded sideways for a decade and not recovered since 2015. Despite this underwhelming long-term track record, XPH's sufficient trading volume positions it for tactical allocation strategies.

Analysis

Based on a quantitative assessment of the healthcare sector, the healthcare providers sub-sector stands out as significantly undervalued relative to its 11-year historical baseline, supported by a strong quality score. In contrast, the pharmaceuticals/biotechnology and life science tools sub-sectors are trading near their historical valuation norms; however, the former exhibits good quality while the latter shows poor quality and a deteriorating value score. The healthcare equipment industry is flagged as moderately overvalued. A specific analysis of the SPDR S&P Pharmaceuticals ETF (XPH) reveals a stark underperformance relative to the broader Health Care Select Sector SPDR ETF (XLV), lagging by 3.7 percentage points on an annualized basis since 2006. This underperformance is attributed to its modified equal-weighting methodology, which has resulted in a decade of sideways price action, failing to recover post-2015 unlike capital-weighted peers such as IHE. Despite the pharmaceutical industry's solid quality metrics, XPH's structural approach has made it an underwhelming long-term investment, though its average daily trading volume of $1.91M makes it viable for tactical positioning.

Key Decisions for Investors

• Investors seeking value within healthcare could consider overweighting the healthcare providers sub-sector, which is identified as significantly undervalued with a favorable quality profile.
• For long-term strategic exposure to pharmaceuticals, investors should be cautious of XPH due to its decade-long underperformance and consider broader sector ETFs like XLV or capital-weighted alternatives that have shown a better historical track record.
• Tactical traders might utilize XPH for short-term opportunities given its sufficient liquidity and unique equal-weighted exposure, but it should not be viewed as a core long-term holding.
• It is prudent to monitor the life science tools sub-sector for further weakness given its poor quality score and be mindful of the moderate overvaluation noted in healthcare equipment.